These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 1924466)

  • 1. The present role of estramustine phosphate in advanced prostate cancer.
    Van Poppel H; Baert L
    Prog Clin Biol Res; 1991; 370():323-41. PubMed ID: 1924466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Final report on low-dose estramustine phosphate (EMP) monotherapy and very low-dose EMP therapy combined with LH-RH agonist for previously untreated advanced prostate cancer.
    Kitamura T; Suzuki M; Nishimatsu H; Kurosaki T; Enomoto Y; Fukuhara H; Kume H; Takeuchi T; Miao L; Jiangang H; Xiaoqiang L
    Aktuelle Urol; 2010 Jan; 41 Suppl 1():S34-40. PubMed ID: 20094950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EMP combination chemotherapy and low-dose monotherapy in advanced prostate cancer.
    Kitamura T; Nishimatsu H; Hamamoto T; Tomita K; Takeuchi T; Ohta N
    Expert Rev Anticancer Ther; 2002 Feb; 2(1):59-71. PubMed ID: 12113067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Potentiation of focal ultrasound treatment of prostate adenocarcinoma by concomitant chemotherapy with estramustine phosphate and paclitaxel].
    Paparel P; Chapelon JY; Curiel L; Rabilloud M; Chesnais S; Gelet A
    Prog Urol; 2004 Feb; 14(1):40-6. PubMed ID: 15098750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor control of locally advanced prostate cancer following combined estramustine, vinblastine, and radiation therapy.
    Khil MS; Kim JH; Bricker LJ; Cerny JC
    Cancer J Sci Am; 1997; 3(5):289-96. PubMed ID: 9327153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose escalation study of intravenous estramustine phosphate in combination with Paclitaxel and Carboplatin in patients with advanced prostate cancer.
    Kelly WK; Zhu AX; Scher H; Curley T; Fallon M; Slovin S; Schwartz L; Larson S; Tong W; Hartley-Asp B; Pellizzoni C; Rocchetti M
    Clin Cancer Res; 2003 Jun; 9(6):2098-107. PubMed ID: 12796374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dramatic decline in prostate-specific antigen by withdrawal of estramustine phosphate in hormone refractory prostate cancer.
    Kobayashi M; Kuramoto H; Ota J; Fujimoto N
    Int J Urol; 2006 Jul; 13(7):1019-21. PubMed ID: 16882080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma.
    Solit DB; Morris M; Slovin S; Curley T; Schwartz L; Larson S; Kattan MW; Hartley-Asp B; Scher HI; Kelly WK
    Cancer; 2003 Nov; 98(9):1842-8. PubMed ID: 14584065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estramustine-based chemotherapy.
    Hudes G
    Semin Urol Oncol; 1997 Feb; 15(1):13-9. PubMed ID: 9050135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thromboembolic events with estramustine phosphate-based chemotherapy in patients with hormone-refractory prostate carcinoma: results of a meta-analysis.
    Lubiniecki GM; Berlin JA; Weinstein RB; Vaughn DJ
    Cancer; 2004 Dec; 101(12):2755-9. PubMed ID: 15536625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-nucleotide polymorphisms in the 17beta-hydroxysteroid dehydrogenase genes might predict the risk of side-effects of estramustine phosphate sodium in prostate cancer patients.
    Suzuki M; Muto S; Hara K; Ozeki T; Yamada Y; Kadowaki T; Tomita K; Kameyama S; Kitamura T
    Int J Urol; 2005 Feb; 12(2):166-72. PubMed ID: 15733111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral estramustine phosphate and oral etoposide for the treatment of hormone-refractory prostate cancer.
    Numata K; Miura N; Azuma K; Karashima T; Kasahara K; Nakatsuzi H; Hashine K; Sumiyoshi Y
    Hinyokika Kiyo; 2007 Feb; 53(2):99-104. PubMed ID: 17352158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunological monitoring during combination of patient-oriented peptide vaccination and estramustine phosphate in patients with metastatic hormone refractory prostate cancer.
    Noguchi M; Itoh K; Suekane S; Morinaga A; Sukehiro A; Suetsugu N; Katagiri K; Yamada A; Noda S
    Prostate; 2004 Jun; 60(1):32-45. PubMed ID: 15129427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer.
    Hudes GR; Nathan FE; Khater C; Greenberg R; Gomella L; Stern C; McAleer C
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):41-5. PubMed ID: 7481860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Estramustine phosphate withdrawal syndrome in relapsed prostate cancer: two case reports].
    Kobayashi S; Tsukamoto T; Tohsaka A; Tohma T
    Hinyokika Kiyo; 2008 Jun; 54(6):423-6. PubMed ID: 18634439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate.
    Mackler NJ; Dunn RL; Hellerstedt B; Cooney KA; Fardig J; Olson K; Pienta KJ; Smith DC
    Cancer; 2006 Jun; 106(12):2617-23. PubMed ID: 16691618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hormonal chemotherapy for hormone-refractory prostate cancer].
    Nishimura K; Nakai Y; Shimizu K; Tokizane T; Arai Y; Inoue H; Takaha N; Nonomura N; Okuyama A; Kamoi K; Ukimura O; Miki T; Koide T; Ichikawa Y; Nishimura K; Sugao H; Yamaguchi S; Takatera H; Uchida K; Miura H
    Hinyokika Kiyo; 2002 Nov; 48(11):713-8. PubMed ID: 12512147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer.
    Galsky MD; Small EJ; Oh WK; Chen I; Smith DC; Colevas AD; Martone L; Curley T; Delacruz A; Scher HI; Kelly WK
    J Clin Oncol; 2005 Mar; 23(7):1439-46. PubMed ID: 15735119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a phase II study.
    Bracarda S; Tonato M; Rosi P; De Angelis V; Mearini E; Cesaroni S; Fornetti P; Porena M
    Cancer; 2000 Mar; 88(6):1438-44. PubMed ID: 10717628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to estramustine phosphate and paclitaxel in patients with advanced breast cancer: a phase I study.
    Keren-Rosenberg S; Muggia FM
    Semin Oncol; 1997 Feb; 24(1 Suppl 3):S26-9. PubMed ID: 9071337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.